Background
Methods
Study setting
Study population
PASC symptoms and conditions
Exposures and covariates
Analyses
Results
Population characteristics
Characteristic | Adults (≥20 years old) | Children and young adults (0 -19 years) | ||||||
---|---|---|---|---|---|---|---|---|
Non-hospitalized | Hospitalized | Non-hospitalized | Hospitalized | |||||
Positive | Negative | Positive | Negative | Positive | Negative | Positive | Negative | |
No. with a SARS-CoV-2 test during March 1st, 2020—May 31st, 2021 AND had any diagnosis in the 540 to 31 days prior to the index date AND a diagnosis in the 31 to 150 days following the index date | 270441 | 2102408 | 45808 | 672923 | 59374 | 520,816 | 2757 | 92696 |
Age in years, mean (SD) | 48.9 (16.8) | 52.8 (17.4) | 59.9 (17.3) | 55.9 (18.4) | 10.2 (6.1) | 8.3 (6.1) | 10.3 (6.5) | 8.9 (6.3) |
Age Group, years (N, % of patients) | ||||||||
0 - < 1 | NA | NA | NA | NA | 4969 (8.4) | 51144 (9.8) | 320 (11.6) | 11649 (12.6) |
1 - < 2 | NA | NA | NA | NA | 3769 (6.3) | 50312 (9.7) | 189 (6.9) | 7415 (8.0) |
2 - < 6 | NA | NA | NA | NA | 8797 (14.8) | 114730 (22.0) | 373 (13.5) | 16778 (18.1) |
6 - < 13 | NA | NA | NA | NA | 14983 (25.2) | 142459 (27.4) | 538 (19.5) | 22058 (23.8) |
13 - < 18 | NA | NA | NA | NA | 18512 (31.2) | 115487 (22.2) | 883 (32.0) | 25433 (27.4) |
18 - < 20 | NA | NA | NA | NA | 8344 (14.1) | 46684 (9.0) | 454 (16.5) | 9363 (10.1) |
20 - < 40 | 89892 (33.2) | 571146 (27.2) | 7361 (16.1) | 172046 (25.6) | NA | NA | NA | NA |
40 - < 55 | 75190 (27.8) | 492470 (23.4) | 8365 (18.3) | 117210 (17.4) | NA | NA | NA | NA |
55 - < 65 | 51300 (19.0) | 421607 (20.1) | 9867 (21.5) | 128344 (19.1) | NA | NA | NA | NA |
65 - < 75 | 34331 (12.7) | 379716 (18.1) | 10064 (22.0) | 138562 (20.6) | NA | NA | NA | NA |
75 - < 85 | 15191 (5.6) | 185106 (8.8) | 7176 (15.7) | 85028 (12.6) | NA | NA | NA | NA |
85 + | 4537 (1.7) | 52363 (2.5) | 2975 (6.5) | 31733 (4.7) | NA | NA | NA | NA |
Sex (N, % of patients) | ||||||||
Female | 170017 (62.9) | 1292859 (61.5) | 24975 (54.5) | 405346 (60.2) | 30502 (51.4) | 255450 (49.0) | 1406 (51.0) | 46404 (50.1) |
Male | 100409 (37.1) | 809350 (38.5) | 20829 (45.5) | 267541 (39.8) | 28868 (48.6) | 265341 (51.0) | 1351 (49.0) | 46286 (49.9) |
Other/Missinga | 13 (0.0) | 199 (0.0) | 1–5 (0.0) | 26 (0.0) | 1–5 (0.0) | 25 (0.0) | 0 (0.0) | 6–10 (0.0) |
Race (N, % of patients) | ||||||||
Asian | 7158 (2.6) | 61996 (2.9) | 1140 (2.5) | 17951 (2.7) | 1620 (2.7) | 15509 (3.0) | 70 (2.5) | 3179 (3.4) |
Black or African American | 42899 (15.9) | 329438 (15.7) | 11906 (26.0) | 121268 (18.0) | 9874 (16.6) | 79953 (15.4) | 686 (24.9) | 16630 (17.9) |
White | 186703 (69.0) | 1474317 (70.1) | 24631 (53.8) | 461579 (68.6) | 37308 (62.8) | 338040 (64.9) | 1268 (46.0) | 56192 (60.6) |
Otherb | 21417 (7.9) | 150712 (7.2) | 6161 (13.4) | 52651 (7.8) | 6768 (11.4) | 55905 (10.7) | 582 (21.1) | 12626 (13.6) |
Missingc | 12254 (4.5) | 85945 (4.1) | 1962 (4.3) | 19471 (2.9) | 3788 (6.4) | 31405 (6.0) | 151 (5.5) | 4056 (4.4) |
Ethnicity (N, % of patients) | ||||||||
Hispanic | 44275 (16.4) | 201931 (9.6) | 8455 (18.5) | 63904 (9.5) | 13739 (23.1) | 83228 (16.0) | 781 (28.3) | 14557 (15.7) |
Non-Hispanic | 206370 (76.3) | 1683892 (80.1) | 34761 (75.9) | 569136 (84.6) | 42440 (71.5) | 401034 (77.0) | 1898 (68.8) | 74749 (80.6) |
Other | 1491 (0.6) | 23112 (1.1) | 50 (0.1) | 643 (0.1) | 173 (0.3) | 2147 (0.4) | 1–5 (0.0) | 353 (0.4) |
Missingc | 18305 (6.8) | 193473 (9.2) | 2538 (5.5) | 39237 (5.8) | 3014 (5.1) | 34407 (6.6) | 76–80 (2.8) | 3035 (3.3) |
BMI (N, % of patients) | ||||||||
Obesityd | 97082 (35.9) | 661683 (31.5) | 18889 (41.2) | 243020 (36.1) | 9372 (15.8) | 74928 (14.4) | 582 (21.1) | 15767 (17.0) |
Missing BMI | 72210 (26.7) | 511513 (24.3) | 9946 (21.7) | 115278 (17.1) | 16826 (28.3) | 135253 (26.0) | 546 (19.8) | 16783 (18.1) |
Number of visits in the 31 to 150 days before the index event, mean (SD) | 5.4 (6.8) | 5.5 (6.8) | 7.6 (9.0) | 8.0 (8.4) | 3.7 (5.7) | 4.0 (6.3) | 10.8 (13.4) | 7.7 (9.9) |
Dexamethasone use (N, % of patients) | 8822 (3.3) | 188156 (8.9) | 16112 (35.2) | 143911 (21.4) | 634 (1.1) | 52284 (10.0) | 511 (18.5) | 27072 (29.2) |
Length of hospital stay, days, mean (SD) | NA | NA | 7.3 (139.8) | 1.1 (277.7) | NA | NA | 6.2 (12.7) | 4.6 (41.9) |
Mechanical ventilation (N, % of patients) | 690 (0.3) | 4484 (0.2) | 2116 (4.6) | 18520 (2.8) | 57 (0.1) | 2275 (0.4) | 158 (5.7) | 4305 (4.6) |
Current smoker e (N, % of patients) | 15923 (5.9) | 176664 (8.4) | 2257 (4.9) | 59378 (8.8) | NA | NA | NA | NA |
Combined comorbidity score, f mean (SD) | 1.0 (2.1) | 1.3 (2.3) | 2.7 (3.3) | 2.1 (2.9) | NA | NA | NA | NA |
Prevalence of symptoms among children and adults
No./total No. (%) | ||||
---|---|---|---|---|
Prevalent symptoms and incident conditions | Non-hospitalized | Hospitalized | ||
Positive | Negative | Positive | Negative | |
Adults (≥20 years) | ||||
Symptoms outcomes | ||||
At least one symptom | 105819/262400 (40.3) | 822370/2020829 (40.7) | 23989/44926 (53.4) | 291712/662295 (44.0) |
Three or more symptoms | 17946/262400 (6.8) | 148606/2020829 (7.4) | 6843/44926 (15.2) | 73005/662295 (11.0) |
Fatigue or muscle weakness | 17188/262400 (6.6) | 126156/2020829 (6.2) | 5454/44926 (12.1) | 58508/662295 (8.8) |
Shortness of breath | 17450/262400 (6.7) | 133948/2020829 (6.6) | 7562/44926 (16.8) | 64494/662295 (9.7) |
Conditions outcomes | ||||
Mental health conditions | 14180/188941 (7.5) | 116175/1426799 (8.1) | 3165/30079 (10.5) | 47330/441280 (10.7) |
Chronic kidney disorders | 2762/252853 (1.1) | 31724/1940517 (1.6) | 1874/35031 (5.3) | 23936/579705 (4.1) |
Diabetes type 1 or type 2 | 4245/225157 (1.9) | 36944/1778370 (2.1) | 2016/29502 (6.8) | 19753/533887 (3.7) |
Hematologic disorders | 2248/265308 (0.8) | 18770/2054644 (0.9) | 2082/43284 (4.8) | 18122/646387 (2.8) |
Major adverse cardiovascular events | 7028/238918 (2.9) | 71936/1783138 (4.0) | 3980/30945 (12.9) | 52227/504033 (10.4) |
Neurological disorders | 8478/236441 (3.6) | 83539/1791423 (4.7) | 3252/34755 (9.4) | 44248/542090 (8.2) |
Respiratory diseases | 8298/229162 (3.6) | 73078/1742318 (4.2) | 4463/32125 (13.9) | 37561/527227 (7.1) |
Children and young adults (0 -19 years) | ||||
Symptoms outcomes | ||||
At least one symptom | 15145/58196 (26.0) | 134017/511383 (26.2) | 1196/2725 (43.9) | 32343/91933 (35.2) |
Three or more symptoms | 1159/58196 (2.0) | 10534/511383 (2.1) | 227/2725 (8.3) | 4841/91933 (5.3) |
Fatigue or muscle weakness | 1338/58196 (2.3) | 10324/511383 (2.0) | 166/2725 (6.1) | 3674/91933 (4.0) |
Shortness of breath | 1345/58196 (2.3) | 11730 /511383 (2.3) | 179/2725 (6.6) | 3676 / 91933 (4.0) |